A Study of RC48-ADC Combined With Triplizumab For First-line Treatment of Urothelial Carcinoma
Status:
Not yet recruiting
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare
RC48-ADC in Combination With Triplizumab to Chemotherapy Alone in Previously Untreated
HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.